GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioxytran Inc (OTCPK:BIXT) » Definitions » Market Cap

Bioxytran (Bioxytran) Market Cap : $22.00 Mil (As of May. 15, 2024)


View and export this data going back to 2009. Start your Free Trial

What is Bioxytran Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Bioxytran's share price for the quarter that ended in Mar. 2024 was $0.1058. Bioxytran's Shares Outstanding (EOP) for the quarter that ended in Mar. 2024 was 173.03 Mil. Therefore, Bioxytran's market cap for the quarter that ended in Mar. 2024 was $18.31 Mil.

Bioxytran's quarterly market cap declined from Sep. 2023 ($24.54 Mil) to Dec. 2023 ($21.85 Mil) and declined from Dec. 2023 ($21.85 Mil) to Mar. 2024 ($18.31 Mil).

Bioxytran's annual market cap increased from Dec. 2021 ($44.34 Mil) to Dec. 2022 ($59.16 Mil) but then declined from Dec. 2022 ($59.16 Mil) to Dec. 2023 ($21.85 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Bioxytran's Enterprise Value for Today is $21.08 Mil.


Bioxytran Market Cap Historical Data

The historical data trend for Bioxytran's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioxytran Market Cap Chart

Bioxytran Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Market Cap
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.21 23.39 44.34 59.16 21.85

Bioxytran Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 54.96 25.09 24.54 21.85 18.31

Competitive Comparison of Bioxytran's Market Cap

For the Biotechnology subindustry, Bioxytran's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bioxytran's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bioxytran's Market Cap distribution charts can be found below:

* The bar in red indicates where Bioxytran's Market Cap falls into.



Bioxytran Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Bioxytran's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )=Share Price (A: Dec. 2023 )*Shares Outstanding (EOP) (A: Dec. 2023 )
=$0.15*145.642
=$21.85

Bioxytran's Market Cap for the quarter that ended in Mar. 2024 is calculated as

Market Cap (Q: Mar. 2024 )=Share Price (Q: Mar. 2024 )*Shares Outstanding (EOP) (Q: Mar. 2024 )
=$0.1058*173.032
=$18.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bioxytran  (OTCPK:BIXT) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Bioxytran Market Cap Related Terms

Thank you for viewing the detailed overview of Bioxytran's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Bioxytran (Bioxytran) Business Description

Traded in Other Exchanges
N/A
Address
75 2nd Avenue, Suite 605, Needham, MA, USA, 02494
Bioxytran Inc is a biopharmaceutical company. The company is engaged in developing anti-necrosis drugs that treat a variety of medical conditions resulting from Ischemia. It is also focusing on the development and commercialization of treatments to prevent catastrophic brain damage resulting from hypoxic conditions following brain stroke. Its product candidate, BXT-25, is an anti-necrosis drug that carries oxygen to tissues when the flow of blood is blocked. Its other drug candidate BXT-252 is a resuscitative agent in a variety of wound healing applications.
Executives
Dale H Conaway director 189 WELLS AVE, NEWTON MA 02459
Alan M Hoberman director 6134 MECHANICSVILLE ROAD, PO BOX 56, MECHANICSVILLE PA 18934
Anders Utter director BIOXYTRAN, INC, 233 NEEDHAM ST., SUITE 300, NEWTON MA 02464
David Platt director, 10 percent owner, officer: CEO 12 APPLETON CIRCLE, NEWTON MA 02459
Hana Chen-walden director 7 RUE ARISTIDE MAILLOL, PARIS I0 75015
Michael Sheikh officer: Chief Communication Officer 1905 S AUDUBON CT, SPOKANE WA 99224
Binder Offer other: No longer 10% owner PASQUALE VIA SETTEMBRIMI 14A, SAN MARIANO 06073, CORCIANO PG ITALY L6 00000
Ola Soderquist 10 percent owner, officer: CFO 47 HAMMOND STREET, UNIT 2, WALTHAM MA 02451
Lawrence W. Bonafide director 78365 HWY 111, SUITE 287, LA QUINTA CA 92253
Nathan Marks director 78365 HWY 111, SUITE 287, LA QUINTA CA 92253
Dave Quincy Farber director, officer: President 78365 HWY 111, SUITE 287, LA QUINTA CA 92253
David Lee director 78365 HWY 111, SUITE 287, LA QUINTA CA 92253
Donita R. Kendig director, officer: Secretary/Treasurer 78365 HWY 11, SUITE 287, LA QUINTA CA 92253
Afcc, Llc 10 percent owner 1621 CENTRAL AVENUE, CHEYENNE WY 82001
Paul W Hai 10 percent owner 20443 TIMBERLINE, BEND OR 97701